Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase ...

Boehringer drug scores in rare kidney disease FSGS

Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.

Boehringer Ingelheim's investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Boehringer Ingelheim today announced results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor for people with primary focal segmental glomerulosclerosis (FSGS). Apecotrep reduced proteinuria, a key indicator associated with kidney damage, by 40% in the 20 mg dose group compared to placebo.1

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase ...

Not intended for the UK

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted,...

Boehringer Ingelheim’s kidney drug reduces proteinuria by 40% in Phase II trial

Data from Boehringer Ingelheim’s Phase II apecotrep study was published in The Lancet and presented at the 2025 ASN’s Kidney WeekThe post Boehringer Ingelheim’s kidney drug reduces proteinuria by 40% in Phase II trial  appeared first on Clinical Trials Arena.